Results 231 to 240 of about 966,197 (400)

Natriuretic Peptides as a Predictor for Delirium After Cardiac Surgery: A Prospective Observational Study. [PDF]

J Clin Med
Huisinga C, Struck E, Mihatsch L, Heyn J, Hagl C, Zwissler B, von Dossow V, Saller T.   +7 more
europepmc   +1 more source

Interplay between natriuretic peptides and left atrial mechanics and the relation to recurrence of atrial fibrillation following catheter ablation. [PDF]

Int J Cardiovasc Imaging, 2023
Olsen FJ, Darkner S, Goetze JP, Chen X, Henningsen K, Pehrson S, Svendsen JH, Biering-Sørensen T.   +7 more
europepmc   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Atrial natriuretic peptide. [PDF]

Archives of Disease in Childhood, 1992
J. Midgley, Neema Modi
openaire   +3 more sources

Differential processing of plasma-ANF in cardiovascular disease [PDF]

, 1987
Arendt, Rainer M., Brenner, Barry M., Gerbes, Alexander L., Ritter, D., Stangl, E.   +4 more
core  

Augmentation of the natriuretic response to atrial natriuretic factor in cirrhosis [PDF]

, 1989
Gerbes, Gerbes, Gerbes, Laffi, Lenz, Petrillo, Salerno   +6 more
core   +1 more source

Atrial Natriuretic Peptides as a Bridge between Atrial Fibrillation, Heart Failure, and Amyloidosis of the Atria. [PDF]

Int J Mol Sci, 2023
Rahbar Kouibaran F, Sabatino M, Barozzi C, Diemberger I.   +3 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Natriuretic Peptides and Soluble ST2 Improve Echocardiographic and Invasive Long-Term Survival Prediction in Patients Evaluated for Diastolic Dysfunction. [PDF]

Int J Mol Sci
Suciu H, Călburean PA, Huțanu A, Oprica M, Opriș DR, Scurtu AC, Stan A, Aniței D, Brînzaniuc K, Hadadi L, Harpa M.   +10 more
europepmc   +1 more source

ATRIAL NATRIURETIC PEPTIDE IN CHILDREN — THE HEART AS AN ENDOCRINE ORGAN [PDF]

, 1985
J Weil, F. Bidlingmaier, C Döhlemann, D Knorr, Ursula Kuhnle, Marcel J. Vogel, Re L   +6 more
openalex   +1 more source